Identification of endothelinâ€“1 in the pathophysiology the prostate

Nature Medicine

1, 944-949

DOI: 10.1038/nm0995-944

Citation Report

#	Article	IF	Citations
1	NEW APPROACHES TO ADJUVANT THERAPY FOR PATIENTS WITH ADVERSE HISTOPATHOLOGIC FINDINGS FOLLOWING RADICAL PROSTATECTOMY. Urologic Clinics of North America, 1996, 23, 685-696.	0.8	4
2	Endocrinology and paracrinology. Molecular Human Reproduction, 1996, 2, 439-444.	1.3	29
3	In VitroExpression of Endothelin-1 (ET-1) and the ET_Aand ET_BET Receptors by the Prostatic Epithelium and Stroma¹. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 508-513.	1.8	22
4	Endothelin attenuates apoptosis in human smooth muscle cells. Biochemical Journal, 1997, 328, 733-737.	1.7	103
5	Differential regulation of extracellular signal-regulated protein kinase 1 and Jun N-terminal kinase 1 by Ca2+ and protein kinase C in endothelin-stimulated Rat-1 cells. Biochemical Journal, 1997, 321, 795-804.	1.7	52
6	Gene Expression and Autoradiographic Localization of Endothelin-1 and its Receptors A and B in the Different Zones of the Normal Human Prostate. Journal of Urology, 1997, 157, 2334-2339.	0.2	38
7	The molecular biology of prostate cancer morbidity and mortality: Accelerated death from ejaculate poisoning?. Urologic Oncology: Seminars and Original Investigations, 1997, 3, 79-84.	0.8	3
8	Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB Journal, 1997, 11, 355-364.	0.2	384
9	Molecular and cellular biology of prostate cancer. Cancer and Metastasis Reviews, 1997, 16, 29-66.	2.7	67
10	Inhibitors of endothelin. Medicinal Research Reviews, 1997, 17, 17-67.	5.0	71
11	Mechanisms of bone metastasis. Cancer, 1997, 80, 1546-1556.	2.0	449
12	Alternatives to death: Understanding androgen-independent prostate cancer. Nature Medicine, 1998, 4, 1011-1012.	15.2	8
13	Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nature Medicine, 1998, 4, 50-57.	15.2	249
14	Modification of tumor blood flow: Current status and future directions. Seminars in Radiation Oncology, 1998, 8, 151-163.	1.0	53
15	Tumour Radiosensitization by High-Oxygenâ€“Content Gases: Influence of the Carbon Dioxide Content of the Inspired Gas on pO2, Microcirculatory Function and Radiosensitivity. International Journal of Radiation Oncology Biology Physics, 1998, 40, 943-951.	0.4	56
16	Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone. European Journal of Cancer, 1998, 34, 240-245.	1.3	132
17	Endothelins as Autocrine Regulators of Tumor Cell Growth. Trends in Endocrinology and Metabolism, 1998, 9, 378-383.	3.1	74
18	Endothelin subtype A receptor antagonist induces osteopenia in growing rats. Metabolism: Clinical and Experimental, 1998, 47, 1403-1407.	1.5	18

#	Article	IF	Citations
19	Serum vascular endothelial growth factor is a candidate biomarker of metastatic tumor response to ex vivo gene therapy of renal cell cancer. Urology, 1998, 51, 327-332.	0.5	23
20	Endothelin receptor expression in human decidua. Molecular Human Reproduction, 1998, 4, 185-193.	1.3	18
21	Role of parathyroid hormone-related peptide in hypercalcemia of malignancy and osteolytic bone disease. Endocrine-Related Cancer, 1998, 5, 15-26.	1.6	3
22	Cancer and Bone*. Endocrine Reviews, 1998, 19, 18-54.	8.9	388
23	Bone Disease in Malignancy. Advances in Organ Biology, 1998, , 709-738.	0.1	0
24	Osteonecrosis of the Femoral Head. Clinical Orthopaedics and Related Research, 1998, 355S, S314-S335.	0.7	118
25	The endothelin system:a novel therapeutic target in cardiovascular disease. Expert Opinion on Emerging Drugs, 1998, 3, 95-112.	1.1	6
26	Potential Role of Endothelin and Nitric Oxide in Physiology and Pathophysiology of the Lower Urinary Tract. Endothelium: Journal of Endothelial Cell Research, 1999, 7, 1-9.	1.7	8
27	Factors regulating the growth of metastatic cancer in bone.. Endocrine-Related Cancer, 1999, 6, 333-347.	1.6	126
28	The Role of the Endothelin Axis in Prostate Cancer. Prostate Journal, 1999, 1, 126-130.	0.2	11
29	Correlation of the osteoblastic phenotype with prostate-specific antigen expression in metastatic prostate cancer: implications for paracrine growth. , 1999, 188, 278-281.		22
30	Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. , 1999, 39, 246-261.		382
31	Endothelin-secreting tumors and the idea of the pseudoectopic hormone secretion in tumors. Medical Hypotheses, 1999, 52, 329-333.	0.8	27
32	Minoxidil and male-pattern alopecia: a potential role for a local regulator of sebum secretion with vasoconstrictive effects?. Medical Hypotheses, 1999, 53, 402-406.	0.8	6
33	SV40 virus transformation down-regulates endothelin receptor. Biochimica Et Biophysica Acta - Molecular Cell Research, 1999, 1450, 35-44.	1.9	4
34	New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology, 1999, 53, 1063-1069.	0.5	160
35	PROSTATE-SPECIFIC ANTIGEN AND OTHER MARKERS OF THERAPEUTIC RESPONSE. Urologic Clinics of North America, 1999, 26, 291-302.	0.8	9
36	Angiogenesis and Cancer Control: From Concept to Therapeutic Trial. Cancer Control, 1999, 6, 1-18.	0.7	104

#	Article	IF	Citations
37	Perioperative Plasma Endothelin-1 and Big Endothelin-1 Concentrations in Elderly Patients Undergoing Major Surgical Procedures. Anesthesia and Analgesia, 1999, 88, 898-903.	1.1	3
38	Perioperative Plasma Endothelin-1 and Big Endothelin-1 Concentrations in Elderly Patients Undergoing Major Surgical Procedures. Anesthesia and Analgesia, 1999, 88, 898-903.	1.1	14
39	Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate, 2000, 44, 77-87.	1.2	131
40	Novel strategies and therapeutics for the treatment of prostate carcinoma. Cancer, 2000, 89, 1329-1348.	2.0	48
41	Decreased constitutive nitric oxide synthase, but increased inducible nitric oxide synthase and endothelin-1 immunoreactivity in aortic endothelial cells of Donryu rats on a cholesterol-enriched diet. The Anatomical Record, 2000, 260, 16-25.	2.3	22
42	The role of endothelin-1 and endothelin receptor antagonists in prostate cancer. BJU International, 2000, 85, 45-48.	1.3	70
43	Augmented expression of endothelin-1, endothelin-3 and the endothelin-B receptor in breast carcinoma. Histopathology, 2000, 36, 161-167.	1.6	69
44	Measurement of endothelin: clinical and research use. Annals of Clinical Biochemistry, 2000, 37, 608-626.	0.8	26
45	Insulin-like Growth Factor I and Urokinase-type Plasminogen Activator Bioregulation System as a Survival Mechanism of Prostate Cancer Cells in Osteoblastic Metastases: Development of Anti-Survival Factor Therapy for Hormone-Refractory Prostate Cancer. Molecular Medicine, 2000, 6, 251-267.	1.9	38
46	Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. British Journal of Cancer, 2000, 83, 360-365.	2.9	115
47	Studies on the Expression of Endothelin, Its Receptor Subtypes, and Converting Enzymes in Lung Cancer and in Human Bronchial Epithelium. American Journal of Respiratory Cell and Molecular Biology, 2000, 22, 422-431.	1.4	93
48	Expression of endothelin 1 and endothelin A receptor in HPVâ€associated cervical carcinoma: new potential targets for anticancer therapy. FASEB Journal, 2000, 14, 2277-2283.	0.2	57
49	Small Bioactive Peptides and Cell Surface Peptidases in Androgen-Independent Prostate Cancer. Cancer Investigation, 2000, 18, 87-96.	0.6	26
50	Biphenylsulfonamide Endothelin Receptor Antagonists. 2. Discovery of 4â€˜-Oxazolyl Biphenylsulfonamides as a New Class of Potent, Highly Selective ETAAntagonists. Journal of Medicinal Chemistry, 2000, 43, 3111-3117.	2.9	32
51	Endothelin Receptor Blockade Inhibits Proliferation of Kaposiâ€™s Sarcoma Cells. American Journal of Pathology, 2001, 158, 841-847.	1.9	34
52	The palliative management of skeletal metastases in prostate cancer: Use of bone-seeking radionuclides and bisphosphonates. Seminars in Nuclear Medicine, 2001, 31, 62-68.	2.5	54
53	Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents. Urology, 2001, 57, 56-63.	0.5	23
54	EXPRESSION OF ENDOTHELIN RECEPTOR A ASSOCIATED WITH PROSTATE CANCER PROGRESSION. Journal of Urology, 2001, 165, 1033-1036.	0.2	116

#	Article	IF	Citations
55	NONANDROGENIC MEDIATORS OF PROSTATIC GROWTH. Hematology/Oncology Clinics of North America, 2001, 15, 459-476.	0.9	10
56	Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer. Expert Opinion on Investigational Drugs, 2001, 10, 1099-1115.	1.9	40
57	Functional Interactions between Tumor and Peripheral Nerve: Changes in Excitability and Morphology of Primary Afferent Fibers in a Murine Model of Cancer Pain. Journal of Neuroscience, 2001, 21, 9367-9376.	1.7	125
58	Expression and Localization of Endothelin Receptors: Implications for the Involvement of Peripheral Glia in Nociception. Journal of Neuroscience, 2001, 21, 999-1006.	1.7	192
59	Pathophysiology of malignant bone pain. , 2001, , 23-34.		0
60	Src-family tyrosine kinases, phosphoinositide 3-kinase and Gab1 regulate extracellular signal-regulated kinase 1 activation induced by the type A endothelin-1 G-protein-coupled receptor. Biochemical Journal, 2001, 360, 77.	1.7	19
61	Endothelin-1 and Metastatic Cancer Pain. Pain Medicine, 2001, 2, 24-27.	0.9	65
62	New therapeutic concepts in prostate cancer. BJU International, 2001, 88, 43-48.	1.3	12
63	Novel therapeutic approaches to cancer patients with bone metastasis. Critical Reviews in Oncology/Hematology, 2001, 40, 239-250.	2.0	36
64	Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. Prostate, 2001, 49, 267-277.	1.2	57
65	Endothelin receptor antagonists in the treatment of prostate cancer. Prostate, 2001, 49, 91-92.	1.2	10
66	Endothelin-1 in human prostatic carcinoma treated with androgen withdrawal. Cancer, 2001, 91, 1933-1939.	2.0	6
67	Decreased wild-type full-length Et-A and -B receptors in neuroblastoma and Ewing sarcoma cells. Medical and Pediatric Oncology, 2001, 36, 142-146.	1.0	4
68	Identification and characterization of neutral endopeptidase (EC 3. 4. 24. 11) from human prostasomes-localization in prostatic tissue and cell lines. Prostate, 2001, 46, 173-183.	1.2	28
69	Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer and Metastasis Reviews, 2001, 20, 333-349.	2.7	179
70	The Treatment of Prostate Cancer. . An Overview of Current Options. Cancer Practice, 2001, 9, 295-306.	0.8	46
71	Increased endothelin-1 in colorectal cancer and reduction of tumour growth by ETA receptor antagonism. British Journal of Cancer, 2001, 85, 1759-1763.	2.9	114
72	Hemochromatosis Gene in Leukemia and Lymphoma. Leukemia and Lymphoma, 2002, 43, 467-477.	0.6	26

#	Article	IF	Citations
73	The New Bisphosphonate, ZometaÂ®(Zoledronic Acid), Decreases Skeletal Complications in Both Osteolytic and Osteoblastic Lesions: A Comparison to Pamidronate. Cancer Investigation, 2002, 20, 45-54.	0.6	170
74	Characterization of a New Endothelin Receptor Ligand by In Vitro Assays. , 2002, 206, 181-198.		0
75	Pharmacological treatments for prostate cancer. Expert Opinion on Investigational Drugs, 2002, 11, 1737-1748.	1.9	9
76	Results of a Phase II Study With Doxorubicin, Etoposide, and Cisplatin in Patients With Fully Characterized Small-Cell Carcinoma of the Prostate. Journal of Clinical Oncology, 2002, 20, 3072-3080.	0.8	242
78	Differential expression of neutral endopeptidase-24.11 (neprilysin) and endothelin-converting enzyme in human prostate cancer cell lines. Clinical Science, 2002, 103, 314S-317S.	1.8	30
79	The Endothelin Receptor. American Journal of Cancer, 2002, 1, 81-91.	0.4	9
81	Metastasis to bone: causes, consequences and therapeutic opportunities. Nature Reviews Cancer, 2002, 2, 584-593.	12.8	2,498
82	Bloodborne biomolecular markers in prostate cancer development and progression. Nature Reviews Cancer, 2002, 2, 918-926.	12.8	56
83	The Endothelin-1 Antagonist, Atrasentan, Improves Time to Progression and Quality of Life in Hormone-Refractory Prostate Cancer. Clinical Prostate Cancer, 2002, 1, 79-80.	2.1	4
84	Efficacy of systemic morphine suggests a fundamental difference in the mechanisms that generate bone cancer vs. inflammatory pain. Pain, 2002, 99, 397-406.	2.0	180
85	GUANOSINE PHOSPHATE BINDING PROTEIN COUPLED RECEPTORS IN PROSTATE CANCER: A REVIEW. Journal of Urology, 2002, 167, 1458-1463.	0.2	50
86	Prostate carcinoma skeletal metastases: Cross-talk between tumor and bone. , 2002, , 197-213.		0
87	Molecular Evidence-Based Use of Bone Resorption-Targeted Therapy in Prostate Cancer Patients at High Risk for Bone Involvement. Molecular Medicine, 2002, 8, 667-675.	1.9	13
88	Estrogens Affect Endothelin-1 mRNA Expression in LNCaP Human Prostate Carcinoma Cells. European Urology, 2002, 41, 568-574.	0.9	4
89	Novel therapies for the treatment of prostate cancer: current clinical trials and development strategies. Surgical Oncology, 2002, 11, 13-23.	0.8	15
90	Physiopathology of cancer metastases in bone and of the changes they induce in bone remodeling. Rendiconti Lincei, 2002, 13, 181-246.	1.0	4
91	Neurotransmitters are regulators for the migration of tumor cells and leukocytes. Cancer Immunology, Immunotherapy, 2002, 51, 467-482.	2.0	80
92	Molecular mechanisms of cancer pain. Nature Reviews Cancer, 2002, 2, 201-209.	12.8	417

#	Article	IF	Citations
93	Endothelin-1 as a target for therapeutic intervention in prostate cancer. Investigational New Drugs, 2002, 20, 173-182.	1.2	67
94	Angiogenesis and the ET-1/ETAReceptor System: Immunohistochemical Expression Analysis in Bone Metastases from Patients with Different Primary Tumors. Angiogenesis, 2003, 6, 225-231.	3.7	12
95	A Proteome Study of Secreted Prostatic Factors Affecting Osteoblastic Activity: Galectin-1 Is Involved in Differentiation of Human Bone Marrow Stromal Cells. Journal of Bone and Mineral Research, 2003, 18, 195-203.	3.1	40
96	Molecular and genetic prognostic factors of prostate cancer. World Journal of Urology, 2003, 21, 265-274.	1.2	18
97	Conservative versus radical therapy of prostate cancer: how have recent advances in molecular markers and imaging enhanced our ability to prognosticate risk?. Seminars in Oncology, 2003, 30, 587-595.	0.8	5
98	Endothelin receptor antagonists in the treatment of prostate cancer. Seminars in Oncology, 2003, 30, 678-688.	0.8	32
99	Role of endothelin-1 in osteoblastic bone metastases. Cancer, 2003, 97, 779-784.	2.0	209
100	Different tumors in bone each give rise to a distinct pattern of skeletal destruction, bone cancer-related pain behaviors and neurochemical changes in the central nervous system. International Journal of Cancer, 2003, 104, 550-558.	2.3	107
101	The comparative biology of skeletal metastasis. Veterinary and Comparative Oncology, 2003, 1, 131-139.	0.8	2
102	Endothelin-1: a multifunctional molecule in cancer. British Journal of Cancer, 2003, 88, 163-166.	2.9	147
103	Endothelin-B receptor activation triggers an endogenous analgesic cascade at sites of peripheral injury. Nature Medicine, 2003, 9, 1055-1061.	15.2	211
104	The endothelin axis: emerging role in cancer. Nature Reviews Cancer, 2003, 3, 110-116.	12.8	527
105	Suppression of Prostate Cancer Induced Bone Remodeling by The Endothelin Receptor a Antagonist Atrasentan. Journal of Urology, 2003, 169, 1143-1149.	0.2	130
106	Prostate cancer: radical prostatectomy. Urologic Clinics of North America, 2003, 30, 703-723.	0.8	20
107	Endothelin Inhibition: Novel Therapy for Prostate Cancer. Journal of Urology, 2003, 170, S65-7; discussion S67-8.	0.2	49
108	Endothelin and Skeletal Metastases in Hormone-Refractory Prostate Cancer. European Urology Supplements, 2003, 2, 15-19.	0.1	2
109	The Role of Endothelin in Hormone-Refractory Prostate Cancer. European Urology Supplements, 2003, 2, 9-14.	0.1	1
110	Atrasentan: The First Endothelin Receptor Antagonist for Hormone-Refractory Prostate Cancer. European Urology Supplements, 2003, 2, 20-27.	0.1	3

#	Article	IF	Citations
111	Clinical Trials of Atrasentan in Hormone-Refractory Prostate Cancer. Clinical Prostate Cancer, 2003, 2, 84-86.	2.1	7
112	A proteome study of secreted prostatic factors affecting osteoblastic activity: identification and characterisation of cyclophilin A. European Journal of Cancer, 2003, 39, 989-995.	1.3	15
113	Endothelin protein expression as a significant prognostic factor in oesophageal squamous cell carcinoma. European Journal of Cancer, 2003, 39, 1409-1415.	1.3	11
114	Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD. Urologic Oncology: Seminars and Original	0.8	5
115	Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Letsch M, Schally AV, Busto R, Bajo AM, Varga JL, Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, and Section of Experimental Medicine, Department of Medicine, Tulane University School of Medicine, New Orleans, LA. Urologic Oncology: Seminars and Original Investigations, 2003, 21, 411-412.	0.8	0
116	Measurement of plasma endothelin-1 in experimental hypertension and in healthy subjects. American Journal of Hypertension, 2003, 16, 515-521.	1.0	27
117	Endothelin-1 promotes osteoprogenitor proliferation and differentiation in fetal rat calvarial cell cultures. Bone, 2003, 33, 673-684.	1.4	73
118	Management of Metastatic Bone Disease and Hypercalcemia of Malignancy. American Journal of Cancer, 2003, 2, 427-438.	0.4	12
119	New Approaches for the Prevention of Bone Metastases in Patients with Prostate Cancer. American Journal of Cancer, 2003, 2, 181-199.	0.4	2
120	Pharmacotherapy of hormone refractory prostate cancer: new developments and challenges. Expert Opinion on Pharmacotherapy, 2003, 4, 875-887.	0.9	13
121	ETA Receptor Blockade Induces Tubular Cell Proliferation and Cyst Growth in Rats with Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2003, 14, 367-376.	3.0	39
122	The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia. Palliative Medicine, 2003, 17, 539-553.	1.3	28
123	Angiogenesis: Basic Mechanisms and Clinical Applications. Seminars in Cardiothoracic and Vascular Anesthesia, 2003, 7, 253-280.	0.4	3
124	Effect of Endothelin-A Receptor Blockade With Atrasentan on Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled Trial. Journal of Clinical Oncology, 2003, 21, 679-689.	0.8	360
125	Endothelin-1 and osteoblastic metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10588-10589.	3.3	24
126	A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10954-10959.	3.3	358
127	Application of structureâ€“metabolism relationships in the identification of a selective endothelin A antagonist, BMS-193884, with favourable pharmacokinetic properties. Xenobiotica, 2003, 33, 1109-1123.	0.5	6
128	Bisphosphonates in the Management of Metastatic Prostate Cancer. Oncology, 2003, 65, 5-11.	0.9	27

#	Article	IF	Citations
129	Mechanisms of Osteoblastic Metastases: Role of Endothelin-1. Clinical Orthopaedics and Related Research, 2003, 415, S67-S74.	0.7	43
130	The Molecular Basis of Skeletal Metastases. Clinical Orthopaedics and Related Research, 2003, 415, S19-S31.	0.7	33
131	Management of Androgen-Independent Prostate Cancer. Cancer Control, 2004, 11, 364-373.	0.7	40
132	Targeting Endothelin Axis in Cancer. , 2004, 119, 293-314.		17
133	Inhibition of Cyclooxygenase-1 and -2 Expression by Targeting the Endothelin A Receptor in Human Ovarian Carcinoma Cells. Clinical Cancer Research, 2004, 10, 4670-4679.	3.2	62
134	Is nitric oxide a key target in the pathogenesis of brain lesions during the development of Alzheimer's disease?. Neurological Research, 2004, 26, 547-553.	0.6	28
135	Endothelin-1 Is Increased in the Breath Condensate of Patients with Non-Small-Cell Lung Cancer. Oncology, 2004, 66, 180-184.	0.9	53
136	Inhibitory Effects of a Selective Endothelin-A Receptor Antagonist YM598 on Endothelin-1-induced Potentiation of Nociception in Formalin-induced and Prostate Cancer-induced Pain Models in Mice. Journal of Cardiovascular Pharmacology, 2004, 44, S479-S482.	0.8	28
137	Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease. Oncology Reports, 2004, 12, 631.	1.2	27
138	Bone Morphogenetic Protein (BMP)-6 Signaling and BMP Antagonist Noggin in Prostate Cancer. Cancer Research, 2004, 64, 8276-8284.	0.4	80
139	The role of bisphosphonates in breast and prostate cancers.. Endocrine-Related Cancer, 2004, 11, 207-224.	1.6	109
140	Stromalâ€“epithelial interactions influence prostate cancer cell invasion by altering the balance of metallopeptidase expression. British Journal of Cancer, 2004, 90, 1577-1582.	2.9	39
141	Atrasentan: targeting the endothelin axis in prostate cancer. Expert Opinion on Investigational Drugs, 2004, 13, 1631-1640.	1.9	30
144	The endothelin system in Morris hepatoma-7777: an endothelin receptor antagonist inhibits growth in vitro and in vivo. British Journal of Pharmacology, 2004, 141, 215-222.	2.7	9
145	Effects of selective endothelin ET A receptor antagonists on endothelin-1-induced potentiation of cancer pain. European Journal of Pharmacology, 2004, 492, 177-182.	1.7	36
147	Cell specific expression of CD10/neutral endopeptidase 24.11 gene in human prostatic tissue and cells. Prostate, 2004, 58, 394-405.	1.2	12
148	Canine prostate stimulates osteoblast function using the endothelin receptors. Prostate, 2004, 59, 148-156.	1.2	16
149	Endothelin A receptor blockade does not alter PSA secretion in prostate cancer cell lines. Prostate, 2004, 60, 175-177.	1.2	4

#	Article	IF	Citations
150	Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. Journal of Cellular Biochemistry, 2004, 91, 718-729.	1.2	251
151	Management of patients with hormone refractory prostate cancer. Clinical Oncology, 2004, 16, 505-516.	0.6	17
152	Plasma endothelin-1 levels in patients with complex regional pain syndrome. European Journal of Pain, 2004, 8, 533-538.	1.4	21
153	The pathophysiology of cancer-induced bone pain: current understanding. Palliative Medicine, 2004, 18, 267-274.	1.3	117
154	Novel therapeutic strategies for androgen-independent prostate cancer: An update. Seminars in Oncology, 2004, 31, 26-32.	0.8	38
155	Clinically related behavioral models: bone cancer pain. Drug Discovery Today: Disease Models, 2004, 1, 127-134.	1.2	0
156	Mechanisms of Bone Metastasis. New England Journal of Medicine, 2004, 350, 1655-1664.	13.9	2,134
157	Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors. Expert Opinion on Investigational Drugs, 2004, 13, 1-19.	1.9	48
158	Angiogenesis-Targeted Therapies in Prostate Cancer. Clinical Prostate Cancer, 2004, 3, 165-173.	2.1	26
159	Endothelin receptors as novel targets in tumor therapy. Journal of Translational Medicine, 2004, 2, 16.	1.8	96
160	Management of Prostate Cancer. , 2004, , .		2
161	D-GPCR: a novel putative G protein-coupled receptor overexpressed in prostate cancer and prostate. Biochemical and Biophysical Research Communications, 2004, 322, 239-249.	1.0	25
162	Endothelin and the tumorigenic component of bone cancer pain. Neuroscience, 2004, 126, 1043-1052.	1.1	117
163	Novel Therapies in Prostate Cancer. European Urology Supplements, 2004, 3, 63-69.	0.1	2
164	Future Directions for Zoledronic Acid and New Agents for the Treatment of Bone Metastases. European Urology Supplements, 2004, 3, 55-62.	0.1	2
165	Pathophysiology of Bone Metastases in Prostate Cancer. European Urology Supplements, 2004, 3, 3-9.	0.1	16
166	Vascular Endothelial Growth Factor Contributes to the Prostate Cancer-Induced Osteoblast Differentiation Mediated by Bone Morphogenetic Protein. Cancer Research, 2004, 64, 994-999.	0.4	139
167	Function and survival of dendritic cells depend on endothelin-1 and endothelin receptor autocrine loops. Blood, 2004, 104, 2107-2115.	0.6	57

#	Article	IF	Citations
168	The Bisphosphonate YM529 Inhibits Osteolytic and Osteoblastic Changes and CXCR-4â€“Induced Invasion in Prostate Cancer. Cancer Research, 2005, 65, 8818-8825.	0.4	62
169	Update in the management of patients with hormone-refractory prostate cancer. Current Opinion in Urology, 2005, 15, 157-162.	0.9	11
171	Management of bone metastases in cancer: A review. Critical Reviews in Oncology/Hematology, 2005, 56, 365-378.	2.0	203
172	Epothilones and the next generation of phase III trials for prostate cancer. BJU International, 2005, 96, 296-302.	1.3	23
173	Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. British Journal of Cancer, 2005, 92, 2148-2152.	2.9	82
174	Osteoblasts in prostate cancer metastasis to bone. Nature Reviews Cancer, 2005, 5, 21-28.	12.8	499
175	Mechanisms of cancer metastasis to the bone. Cell Research, 2005, 15, 57-62.	5.7	270
176	Expression of the Endothelin Axis in Bladder Cancer: Relationship to Clinicopathologic Parameters and Long-term Survival. European Urology, 2005, 47, 593-600.	0.9	24
177	Molecular Mechanisms of Breast Cancer Metastases to Bone. Clinical Breast Cancer, 2005, 5, S46-S53.	1.1	149
178	Endothelin receptor antagonists. World Journal of Urology, 2005, 23, 19-27.	1.2	51
179	Role of endothelin axis in progression to aggressive phenotype of prostate adenocarcinoma. Prostate, 2005, 65, 27-34.	1.2	32
181	Editorial [Hot Topic: The Endothelin System: Vascular Targets for Therapy in Disease (Guest Editor:) Tj ETQq1 1 0.784314 rgBT /Overlo	0.8	0
182	Emerging role of the endothelin axis in ovarian tumor progression. Endocrine-Related Cancer, 2005, 12, 761-772.	1.6	80
183	Achieving Treatment Goals for Hormoneâ€Refractory Prostate Cancer with Chemotherapy. Oncologist, 2005, 10, 30-39.	1.9	32
184	Vascular Endothelial Growth Factor Contributes to Prostate Cancerâ€“Mediated Osteoblastic Activity. Cancer Research, 2005, 65, 10921-10929.	0.4	91
186	Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer. Expert Review of Anticancer Therapy, 2005, 5, 419-427.	1.1	28
189	Bone Morphogenetic Protein-6 Promotes Osteoblastic Prostate Cancer Bone Metastases through a Dual Mechanism. Cancer Research, 2005, 65, 8274-8285.	0.4	189
191	Endothelin-1 and Angiogenesis in Cancer. Current Vascular Pharmacology, 2005, 3, 309-314.	0.8	79

#	Article	IF	Citations
192	Anti-Progressive Effect of Neutral Endopeptidase 24.11 (NEP/CD10) on Cervical Carcinoma in vitro and in vivo. Oncology, 2005, 69, 52-62.	0.9	39
193	Molecular and Biological Mechanisms of Bone Metastasis. EAU Update Series, 2005, 3, 214-226.	0.5	47
195	Endothelin-1 Inhibits Apoptosis in Prostate Cancer. Neoplasia, 2005, 7, 631-637.	2.3	86
196	Targeted therapies for prostate cancer. Expert Opinion on Therapeutic Targets, 2005, 9, 283-298.	1.5	12
197	New therapeutic agents for the treatment of bone diseases. Expert Opinion on Biological Therapy, 2005, 5, 817-832.	1.4	31
198	Expression of endothelin-1 is related to poor prognosis in non-small cell lung carcinoma. European Journal of Cancer, 2005, 41, 2828-2835.	1.3	45
199	PTHrP fragments 1-16 and 1-23 do not bind to either the ETA or the ETB endothelin receptors. Peptides, 2005, 26, 1436-1440.	1.2	6
200	Future therapies in hormone-refractory prostate cancer. Urology, 2005, 65, 9-16.	0.5	54
201	Endothelin Receptor A Blockade Enhances Taxane Effects in Prostate Cancer. Neoplasia, 2006, 8, 725-732.	2.3	43
202	Targeting Factors Involved in Bone Remodeling as Treatment Strategies in Prostate Cancer Bone Metastasis. Clinical Cancer Research, 2006, 12, 6285s-6290s.	3.2	62
203	Basic Mechanisms Responsible for Osteolytic and Osteoblastic Bone Metastases: Fig. 1.. Clinical Cancer Research, 2006, 12, 6213s-6216s.	3.2	444
204	Transcript quantification of Dresden G protein-coupled receptor (D-GPCR) in primary prostate cancer tissue pairs. Cancer Letters, 2006, 236, 95-104.	3.2	17
206	Prostate Cancer Progression and Surrounding Microenvironment. International Journal of Biological Markers, 2006, 21, 88-95.	0.7	15
207	Osteoblastic Metastases. , 2006, , 41-50.		0
208	Endothelin-1 (ET-1) promotes MMP-2 and MMP-9 induction involving the transcription factor NF-Î²B in human osteosarcoma. Clinical Science, 2006, 110, 645-654.	1.8	93
209	Pathophysiology and Management of Surgical and Chronic Oral Pain in Dogs and Cats. Journal of Veterinary Dentistry, 2006, 23, 50-60.	0.1	47
210	Similarities and Differences in Tumor Growth, Skeletal Remodeling and Pain in an Osteolytic and Osteoblastic Model of Bone Cancer. Clinical Journal of Pain, 2006, 22, 587-600.	0.8	78
211	Prostate-specific antigen induces apoptosis of osteoclast precursors: Potential Role in osteoblastic bone metastases of prostate cancer. Prostate, 2006, 66, 1573-1584.	1.2	42

#	Article	IF	Citations
212	The Role of Oxidative Stress in the Pathophysiology of Cerebrovascular Lesions in Alzheimer's Disease. Brain Pathology, 2002, 12, 21-35.	2.1	146
213	Endothelin Antagonism with Bosentan: Current Status and Future Perspectives. Cardiovascular Drug Reviews, 2002, 20, 1-18.	4.4	11
214	Pathogenesis of bone metastasis: a review. Journal of Oral Pathology and Medicine, 2006, 35, 129-135.	1.4	36
215	Therapeutic targeting of the endothelin a receptor in human nasopharyngeal carcinoma. Cancer Science, 2006, 97, 1388-1395.	1.7	19
216	Flow cytometric technique for determination of prostasomal quantity, size and expression of CD10, CD13, CD26 and CD59 in human seminal plasma. Journal of Developmental and Physical Disabilities, 2006, 29, 331-338.	3.6	28
217	Cancer pain and its impact on diagnosis, survival and quality of life. Nature Reviews Neuroscience, 2006, 7, 797-809.	4.9	364
218	Targeted approaches for the management of metastatic prostate cancer. Current Oncology Reports, 2006, 8, 206-212.	1.8	4
219	Effect of YM598, a selective endothelin ETA receptor antagonist, on endothelin-1-induced bone formation. European Journal of Pharmacology, 2006, 543, 14-20.	1.7	9
220	Molecular Correlates of Site-Specific Metastasis. Seminars in Radiation Oncology, 2006, 16, 102-110.	1.0	22
221	The metastatic cascade in prostate cancer. Surgical Oncology, 2006, 15, 117-128.	0.8	98
222	Endothelin system in oral squamous carcinoma cells: Specific siRNA targeting of ECE-1 blocks cell proliferation. International Journal of Cancer, 2006, 118, 1645-1652.	2.3	34
223	The endothelin axis in urologic tumors: mechanisms of tumor biology and therapeutic implications. Expert Review of Anticancer Therapy, 2006, 6, 73-81.	1.1	31
224	Neutral Endopeptidase Expressed by Decidualized Stromal Cells Suppresses Akt Phosphorylation and Deoxyribonucleic Acid Synthesis Induced by Endothelin-1 in Human Endometrium. Endocrinology, 2006, 147, 5153-5159.	1.4	19
225	Prostate-Specific Antigen Modulates Genes Involved in Bone Remodeling and Induces Osteoblast Differentiation of Human Osteosarcoma Cell Line SaOS-2. Clinical Cancer Research, 2006, 12, 1420-1430.	3.2	48
226	1Â, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis, 2006, 27, 1883-1893.	1.3	153
227	Multiple signaling pathways are involved in endothelin-1-induced brain endothelial cell migration. American Journal of Physiology - Cell Physiology, 2006, 291, C155-C164.	2.1	16
228	Targeting Bone Metastasis in Prostate Cancer with Endothelin Receptor Antagonists: Fig. 1.. Clinical Cancer Research, 2006, 12, 6296s-6300s.	3.2	126
229	Pharmacotherapy for prostate cancer, with emphasis on hormonal treatments. Expert Opinion on Pharmacotherapy, 2006, 7, 1685-1699.	0.9	6

#	Article	IF	Citations
230	Management of prostate cancer. Part 3: metastatic disease. Expert Review of Anticancer Therapy, 2006, 6, 813-821.	1.1	3
231	New molecular targets in advanced prostate cancer. Expert Review of Anticancer Therapy, 2006, 6, 993-1002.	1.1	9
232	Dickkopf Homolog 1 Mediates Endothelin-1-Stimulated New Bone Formation. Molecular Endocrinology, 2007, 21, 486-498.	3.7	169
233	Endothelin Receptor Antagonists in Cancer Therapy. Cancer Investigation, 2007, 25, 785-794.	0.6	56
234	In vitro and In vivo Molecular Evidence for Better Therapeutic Efficacy of ABT-627 and Taxotere Combination in Prostate Cancer. Cancer Research, 2007, 67, 3818-3826.	0.4	91
235	Endothelin signaling in osteoblasts: global genome view and implication of the calcineurin/NFAT pathway. Molecular Cancer Therapeutics, 2007, 6, 253-261.	1.9	30
236	Molecular and Genetic Profiling of Prostate Cancer: Implications for Future Therapy. Current Cancer Therapy Reviews, 2007, 3, 25-36.	0.2	5
237	Epithelial-Mesenchymal Transition in Ovarian Cancer Progression: A Crucial Role for the Endothelin Axis. Cells Tissues Organs, 2007, 185, 85-94.	1.3	63
238	Bone metastasis in prostate cancer: Molecular and cellular mechanisms (Review). International Journal of Molecular Medicine, 2007, , .	1.8	22
239	Prostate Cancer Epigenetics: A Review on Gene Regulation. Gene Regulation and Systems Biology, 2007, 1, GRSB.S398.	2.3	11
240	Bone metastases in prostate cancer: a targeted approach. Current Opinion in Oncology, 2007, 19, 254-258.	1.1	13
241	Distinct Patterns of Endothelin Axis Expression in Primary Prostate Cancer. Urology, 2007, 70, 209-215.	0.5	20
242	Endothelin-1 promotes cell survival in renal cell carcinoma through the ETA receptor. Cancer Letters, 2007, 246, 139-148.	3.2	56
243	When prostate cancer meets bone: Control by wnts. Cancer Letters, 2007, 253, 170-179.	3.2	41
244	Advanced Prostate Cancer: Hormones and Beyond. European Urology Supplements, 2007, 6, 354-364.	0.1	5
245	Endothelin Potentiates TRPV1 via ETAReceptor-Mediated Activation of Protein Kinase C. Molecular Pain, 2007, 3, 1744-8069-3-35.	1.0	68
246	Metastasis of Prostate Cancer. Cancer Metastasis - Biology and Treatment, 2007, , .	0.1	4
247	Bone Directed Therapies for Prostate Cancer. Journal of Urology, 2007, 178, S42-8.	0.2	10

#	Article	IF	Citations
249	Biology and Therapeutic Basis of Prostate Cancer Bone Metastasis. , 2007, , 175-191.		0
250	Strategies for the Implementation of Chemotherapy and Radiotherapy. , 2008, , 309-335.		0
251	Biology and clinical management of prostate cancer bone metastasis. Frontiers in Bioscience - Landmark, 2007, 12, 3273.	3.0	35
252	Abnormal DNA methylation, epigenetics, and prostate cancer. Frontiers in Bioscience - Landmark, 2007, 12, 4254.	3.0	132
253	The role of tumor microenvironment in prostate cancer bone metastasis. Journal of Cellular Biochemistry, 2007, 101, 873-886.	1.2	94
254	A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormoneâ€refractory prostate cancer. Cancer, 2007, 110, 1959-1966.	2.0	276
255	Endothelins in the urinary tract. BJU International, 2007, 86, 97-106.	1.3	20
256	Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer?. Prostate, 2007, 67, 312-329.	1.2	88
257	IRL-1620, a tumor selective vasodilator, augments the uptake and efficacy of chemotherapeutic agents in prostate tumor rats. Prostate, 2007, 67, 701-713.	1.2	14
258	G-protein-coupled receptors and cancer. Nature Reviews Cancer, 2007, 7, 79-94.	12.8	1,153
259	Chemotherapy for the treatment of hormone-refractory prostate cancer. International Journal of Clinical Practice, 2007, 61, 2064-2070.	0.8	32
260	Immunohistochemical Expression of Endothelin-1 and Endothelin-A and Endothelin-B Receptors in High-Grade Prostatic Intraepithelial Neoplasia and Prostate Cancer. European Urology, 2007, 52, 1682-1690.	0.9	26
261	The central role of osteoblasts in the metastasis of prostate cancer. Cancer and Metastasis Reviews, 2007, 25, 601-609.	2.7	31
262	Metastasis: the seed and soil theory gains identity. Cancer and Metastasis Reviews, 2007, 26, 705-715.	2.7	129
263	Bone metabolism and new targets for intervention. Current Prostate Reports, 2007, 5, 55-60.	0.1	0
264	Bone metabolism and new targets for intervention. Current Urology Reports, 2007, 8, 233-238.	1.0	2
265	Role of the endothelins and endothelin receptors in cancer cell signaling and angiogenesis. Targeted Oncology, 2007, 2, 181-191.	1.7	0
266	Effective chemotherapy for hormone-refractory prostate cancer (HRPC): Present status and perspectives with taxane-based treatments. Critical Reviews in Oncology/Hematology, 2007, 61, 176-185.	2.0	42

#	Article	IF	Citations
267	The bone microenvironment in metastasis; what is special about bone?. Cancer and Metastasis Reviews, 2008, 27, 41-55.	2.7	247
268	A new era in prostate cancer therapy: new targets and novel therapeutics. Targeted Oncology, 2008, 3, 31-39.	1.7	0
269	Potentiation of 2â€Methoxyestradiolâ€Induced cytotoxicity by blocking endothelin A receptor in prostate cancer cells. Prostate, 2008, 68, 679-689.	1.2	6
270	Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormoneâ€refractory prostate cancer. Cancer, 2008, 113, 2478-2487.	2.0	230
271	Development of drugs against hormoneâ€refractory prostate cancer. Drug Development Research, 2008, 69, 431-450.	1.4	5
272	Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid. International Journal of Cancer, 2008, 122, 751-760.	2.3	15
273	Molecular and prognostic markers in prostate cancer. Apmis, 2008, 116, 1-62.	0.9	0
274	Isoforms of endothelin-converting enzyme-1 (ECE-1) have opposing effects on prostate cancer cell invasion. British Journal of Cancer, 2008, 99, 1114-1120.	2.9	34
275	Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment. International Journal of Urology, 2008, 15, 19-26.	0.5	29
276	Current and future treatments of bone metastases. Expert Opinion on Emerging Drugs, 2008, 13, 609-627.	1.0	14
277	Mechanisms of bone metastasis in prostate cancer: clinical implications. Best Practice and Research in Clinical Endocrinology and Metabolism, 2008, 22, 341-355.	2.2	93
279	ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer. Expert Opinion on Investigational Drugs, 2008, 17, 1237-1245.	1.9	33
280	Targeted Cancer Therapy. , 2008, , .		11
281	Endothelin-1 enhances proliferation of lung cancer cells by increasing intracellular free Ca2+. Life Sciences, 2008, 82, 764-771.	2.0	35
282	The Treatment of Prostate Cancer.. Cancer Practice, 2001, 9, 295-306.	0.8	3
283	Soluble ErbB3 Levels in Bone Marrow and Plasma of Men with Prostate Cancer. Clinical Cancer Research, 2008, 14, 3729-3736.	3.2	23
284	A Phase I-II Study of Docetaxel and Atrasentan in Men with Castration-Resistant Metastatic Prostate Cancer. Clinical Cancer Research, 2008, 14, 6270-6276.	3.2	66
285	Targeting the endothelin system: novel therapeutic options in gynecological, urological and breast cancers. Expert Review of Anticancer Therapy, 2008, 8, 1481-1493.	1.1	22

#	Article	IF	Citations
287	Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer. Annals of Oncology, 2008, 19, vii91-vii95.	0.6	26
289	Promising Novel Cytotoxic Agents and Combinations in Metastatic Prostate Cancer. Cancer Journal (Sudbury, Mass), 2008, 14, 15-19.	1.0	11
290	Systemic nonhormonal management of advanced prostate cancer and its likely impact on patients' survival and quality of life. Anti-Cancer Drugs, 2008, 19, 645-653.	0.7	7
291	Localized Osteolysis. , 2008, , 1391-1413.		0
292	Altered sensitivity to mechanical stimulation during prolonged subcutaneous administration of endothelin-1 in rats. Journal of Pain Research, 2009, 2, 67.	0.8	1
293	CANCER PAIN MANAGEMENT. , 2009, , 97-106.		2
294	Phase I Study of Concurrent Weekly Docetaxel and Repeated Samarium-153 Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer. Journal of Clinical Oncology, 2009, 27, 3319-3324.	0.8	46
295	Endothelin-1 inhibits prostate cancer growth in vivo through vasoconstriction of tumor-feeding arterioles. Cancer Biology and Therapy, 2009, 8, 720-729.	1.5	15
296	Agents Targeting Prostate Cancer Bone Metastasis. Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 1079-1088.	0.9	5
297	Endothelin B Receptor, a New Target in Cancer Immune Therapy. Clinical Cancer Research, 2009, 15, 4521-4528.	3.2	99
298	Prostatakarzinom. , 2009, , 485-635.		0
299	Emerging drugs for prostate cancer. Expert Opinion on Emerging Drugs, 2009, 14, 455-470.	1.0	7
300	Prostate cancer in dogs: Comparative and clinical aspects. Veterinary Journal, 2009, 180, 149-162.	0.6	179
301	Nociceptive sensitization by endothelin-1. Brain Research Reviews, 2009, 60, 36-42.	9.1	37
302	Expression of the Endothelin Axis in Noninvasive and Superficially Invasive Bladder Cancer: Relation to Clinicopathologic and Molecular Prognostic Parameters. European Urology, 2009, 56, 837-847.	0.9	23
303	Editorial Comment on: Expression of the Endothelin Axis in Noninvasive and Superficially Invasive Bladder Cancer: Relation to Clinicopathologic and Molecular Prognostic Parameters. European Urology, 2009, 56, 845-846.	0.9	1
304	Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets. European Urology, 2009, 56, 594-605.	0.9	174
305	Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model. Clinical and Experimental Metastasis, 2009, 26, 981-992.	1.7	28

#	Article	IF	Citations
307	Molecular insights into substrate specificity of prostate specific antigen through structural modeling. Proteins: Structure, Function and Bioinformatics, 2009, 77, 984-993.	1.5	14
308	Endothelin receptor antagonism and cancer. European Journal of Clinical Investigation, 2009, 39, 74-77.	1.7	37
309	Molecular mechanisms of metastasis in prostate cancer. Asian Journal of Andrology, 2009, 11, 57-67.	0.8	78
310	Osteotropic cancers: From primary tumor to bone. Cancer Letters, 2009, 273, 177-193.	3.2	141
311	The critical role of the bone microenvironment in cancer metastases. Molecular and Cellular Endocrinology, 2009, 310, 71-81.	1.6	128
312	TLR2 and TLR4 agonists induce production of the vasoactive peptide endothelin-1 by human dendritic cells. Molecular Immunology, 2009, 46, 3178-3182.	1.0	31
314	Endothelin Receptors as Therapeutic Targets in Castration-Resistant Prostate Cancer. European Urology Supplements, 2009, 8, 20-28.	0.1	7
315	Emerging therapies in castrate-resistant prostate cancer. Current Opinion in Oncology, 2009, 21, 260-265.	1.1	74
316	Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054. Anti-Cancer Drugs, 2009, 20, 83-88.	0.7	41
317	Targeting the endothelin receptor in prostate cancer bone metastasis: Back to the mouse?. Cancer Biology and Therapy, 2010, 9, 615-617.	1.5	6
318	Update on castrate-resistant prostate cancer: 2010. Current Opinion in Oncology, 2010, 22, 263-267.	1.1	61
319	Endothelin-1 regulates rat bone sialoprotein gene transcription. Journal of Oral Science, 2010, 52, 221-229.	0.7	5
320	Endothelinâ€"Biology and disease. Cellular Signalling, 2010, 22, 1615-1625.	1.7	179
321	Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer, 2010, 116, 1406-1418.	2.0	157
322	Angiogenesis as a strategic target for prostate cancer therapy. Medicinal Research Reviews, 2010, 30, 23-66.	5.0	42
323	Mapping proâ€•and antiangiogenic factors on the surface of prostasomes of normal and malignant cell origin. Prostate, 2010, 70, 834-847.	1.2	6
324	PSA reduces prostate cancer cell motility by stimulating TRPM8 activity and plasma membrane expression. Oncogene, 2010, 29, 4611-4616.	2.6	86
325	Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene, 2010, 29, 3196-3207.	2.6	72

#	Article	IF	Citations
326	Tumor-Bone Cell Interactions in Bone Metastases. , 2010, , 9-40.		1
327	Effect of endothelin-1 on cyclooxygenase-2 expression in human hormone refractory prostate cancer cells. Oncology Letters, 2010, 1, 495-499.	0.8	1
328	Research in Castration-Resistant Rostate Cancer: What Does the Future Hold?. Current Oncology, 2010, 17, 80-86.	0.9	9
329	Update on options for treatment of metastatic castration-resistant prostate cancer. OncoTargets and Therapy, 2010, 3, 39.	1.0	26
330	Onset of peripheral arterial disease: role of endothelin in endothelial dysfunctionâ˜†. Interactive Cardiovascular and Thoracic Surgery, 2010, 10, 760-765.	0.5	16
331	Anti-endothelin drugs in solid tumors. Expert Opinion on Emerging Drugs, 2010, 15, 27-40.	1.0	16
332	Review: Castration-resistant prostate cancer: new science and therapeutic prospects. Therapeutic Advances in Medical Oncology, 2010, 2, 189-207.	1.4	25
334	Bone-specific growth inhibition of prostate cancer metastasis by Atrasentan. Cancer Biology and Therapy, 2010, 9, 607-614.	1.5	29
336	Clinical Significance of Polymorphism and Expression of Chromogranin A and Endothelin-1 in Prostate Cancer. Journal of Urology, 2010, 184, 1182-1188.	0.2	16
337	Novel Targeted Therapies for Prostate Cancer. Urologic Clinics of North America, 2010, 37, 105-119.	0.8	9
339	Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis. Molecular Cancer, 2010, 9, 258.	7.9	146
340	Osteolytic prostate cancer cells induce the expression of specific cytokines in bone-forming osteoblasts through a Stat3/5-dependent mechanism. Bone, 2010, 46, 524-533.	1.4	16
341	Targeted therapeutic approaches for hormone-refractory prostate cancer. Cancer Treatment Reviews, 2010, 36, 122-130.	3.4	69
342	Tumorâ€“stroma co-evolution in prostate cancer progression and metastasis. Seminars in Cell and Developmental Biology, 2010, 21, 26-32.	2.3	123
343	ECE-1 influences prostate cancer cell invasion via ET-1-mediated FAK phosphorylation and ET-1-independent mechanismsThis article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research.. Canadian Journal of Physiology and Pharmacology, 2010, 88, 850-854.	0.7	16
344	Zibotentan for the treatment of castrate-resistant prostate cancer. Expert Opinion on Investigational Drugs, 2010, 19, 899-908.	1.9	32
345	Bone metastasis in prostate cancer: emerging therapeutic strategies. Nature Reviews Clinical Oncology, 2011, 8, 357-368.	12.5	226
346	Oxidative Stress-Induced Mitochondrial Damage as a Hallmark for Drug Development in the Context of the Neurodegeneration, Cardiovascular, and Cerebrovascular Diseases. , 2011, , 2083-2126.		0

#	Article	IF	Citations
347	Tumorâ€“stroma: role of the tumor microenvironment during bone metastasis: unveiling therapeutic targets. Drug Discovery Today: Disease Models, 2011, 8, 87-93.	1.2	3
348	Dysregulation of developmental pathways in bone metastasis. Bone, 2011, 48, 16-22.	1.4	37
349	Physiopathology of Spine Metastasis. International Journal of Surgical Oncology, 2011, 2011, 1-8.	0.3	115
350	Bone morphogenetic protein and bone metastasis, implication and therapeutic potential. Frontiers in Bioscience - Landmark, 2011, 16, 865.	3.0	49
351	Endothelinâ€1: a predictor of extracapsular extension in clinically localized prostate cancer?. BJU International, 2011, 108, E104-9.	1.3	4
352	IMPROVED SURVIVAL PROSPECTS FOR PATIENTS WITH CASTRATIONâ€RESISTANT PROSTATE CANCER. BJU International, 2011, 107, 697-700.	1.3	8
353	Current and emerging treatment modalities for metastatic castrationâ€resistant prostate cancer. BJU International, 2011, 107, 13-20.	1.3	35
354	Role of the endothelin axis and its antagonists in the treatment of cancer. British Journal of Pharmacology, 2011, 163, 220-233.	2.7	103
355	Cancer to bone: a fatal attraction. Nature Reviews Cancer, 2011, 11, 411-425.	12.8	1,047
356	A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer. Investigational New Drugs, 2011, 29, 118-125.	1.2	26
357	Endothelin-1 Promotes Osteosarcoma Cell Invasion and Survival against Cisplatin-induced Apoptosis. Clinical Orthopaedics and Related Research, 2011, 469, 3190-3199.	0.7	26
358	Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies. BMC Clinical Pharmacology, 2011, 11, 3.	2.5	24
359	Inverse baseline expression pattern of the NEP/neuropeptides and NFÎºB/proteasome pathways in androgen-dependent and androgen-independent prostate cancer cells. Cancer Cell International, 2011, 11, 13.	1.8	16
360	Herpesvirus saimiriâ€based endothelinâ€converting enzymeâ€1 shRNA expression decreases prostate cancer cell invasion and migration. International Journal of Cancer, 2011, 129, 586-598.	2.3	13
361	Steps in prostate cancer progression that lead to bone metastasis. International Journal of Cancer, 2011, 128, 2545-2561.	2.3	152
362	Regulation of postnatal trabecular bone formation by the osteoblast endothelin A receptor. Journal of Bone and Mineral Research, 2011, 26, 2523-2536.	3.1	30
363	Mechanism of cancer-induced bone destruction: An association of connective tissue growth factor (CTGF/CCN2) in the bone metastasis. Japanese Dental Science Review, 2011, 47, 13-22.	2.0	5
364	Castration-Resistant Prostate Cancer: Targeted Therapies and Individualized Treatment. Oncologist, 2011, 16, 264-275.	1.9	27

#	Article	IF	Citations
365	Bone Metastatic Disease: Taking Aim at New Therapeutic Targets. Current Medicinal Chemistry, 2011, 18, 3093-3115.	1.2	23
366	Electroporation-Aided DNA Immunization Generates Polyclonal Antibodies Against the Native Conformation of Human Endothelin B Receptor. DNA and Cell Biology, 2011, 30, 727-737.	0.9	13
367	Castration-Resistant Prostate Cancer: Targeted Therapies. Chemotherapy, 2011, 57, 115-127.	0.8	15
368	Drug development for metastatic castration-resistant prostate cancer: current status and future perspectives. Future Oncology, 2011, 7, 551-558.	1.1	8
369	Expression of Neutral Endopeptidase, Endothelin-1, and Nuclear Factor Kappa B in Prostate Cancer: Interrelations and Associations with Prostate-Specific Antigen Recurrence after Radical Prostatectomy. Prostate Cancer, 2012, 2012, 1-8.	0.4	7
370	Overcoming Drug Resistance and Treating Advanced Prostate Cancer. Current Drug Targets, 2012, 13, 1308-1323.	1.0	94
371	Knockdown of endothelin A receptor expression inhibits osteosarcoma pulmonary metastasis in an orthotopic xenograft mouse model. Molecular Medicine Reports, 2012, 5, 1391-5.	1.1	16
373	Biology of Bone Metastases. Cancer Control, 2012, 19, 92-101.	0.7	92
374	MicroRNA-1 inhibits proliferation of hepatocarcinoma cells by targeting endothelin-1. Life Sciences, 2012, 91, 440-447.	2.0	62
376	Biology of Castration-Recurrent Prostate Cancer. Urologic Clinics of North America, 2012, 39, 435-452.	0.8	28
377	Neuropeptide-inducible upregulation of proteasome activity precedes nuclear factor kappa B activation in androgen-independent prostate cancer cells. Cancer Cell International, 2012, 12, 31.	1.8	5
379	Permissive role of endothelin receptors in tumor metastasis. Life Sciences, 2012, 91, 522-527.	2.0	24
380	Osteolytic and Osteoblastic Bone Metastases: Two Extremes of the Same Spectrum?. Recent Results in Cancer Research, 2012, 192, 225-233.	1.8	32
381	Prevention of Bone Metastases. Recent Results in Cancer Research, 2012, , .	1.8	4
382	Painful Decisions for Senior Pets. Veterinary Clinics of North America - Small Animal Practice, 2012, 42, 727-748.	0.5	12
383	Castration-resistant prostate cancer: systemic therapy in 2012. Clinics, 2012, 67, 389-394.	0.6	24
384	Endothelinâ€1 promotes MMPâ€13 production and migration in human chondrosarcoma cells through FAK/PI3K/Akt/mTOR pathways. Journal of Cellular Physiology, 2012, 227, 3016-3026.	2.0	69
385	The application of genomic and molecular data in the treatment of chronic cancer pain. Journal of Surgical Oncology, 2012, 105, 494-501.	0.8	17

#	Article	IF	Citations
386	Molecular Pathology of Cancer Metastasis: Suggestions for Future Therapy. , 2012, , 469-515.		2
387	Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells. International Journal of Urology, 2012, 19, 565-574.	0.5	11
388	Clinical development of novel therapeutics for castrationâ€resistant prostate cancer. Ca-A Cancer Journal for Clinicians, 2012, 62, 299-308.	157.7	40
389	Novel therapeutics for the management of castrationâ€resistant prostate cancer (CRPC). BJU International, 2012, 109, 968-985.	1.3	28
390	Dasatinib combined with docetaxel for castrationâ€resistant prostate cancer. Cancer, 2012, 118, 63-71.	2.0	138
391	Targeting the endothelin axis in prostate carcinoma. Tumor Biology, 2012, 33, 421-426.	0.8	29
392	Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nature Reviews Cancer, 2013, 13, 637-651.	12.8	282
393	Ligand-based drug design for human endothelin converting enzyme-1 inhibitors. Medicinal Chemistry Research, 2013, 22, 4401-4409.	1.1	1
394	Current, new and novel therapy for castration-resistant prostate cancer. Expert Review of Anticancer Therapy, 2013, 13, 819-827.	1.1	9
395	Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments. Inflammopharmacology, 2013, 21, 339-363.	1.9	38
396	New and Emerging Therapies for Bone Metastases in Genitourinary Cancers. European Urology, 2013, 63, 309-320.	0.9	42
398	Unravelling the molecular complexity of <scp>GPCR</scp>â€mediated <scp>EGFR</scp> transactivation using functional genomics approaches. FEBS Journal, 2013, 280, 5258-5268.	2.2	53
399	Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncology, The, 2013, 14, 893-900.	5.1	139
400	Molecular Mechanisms of Castrate Resistant Prostate Cancer. , 2013, , 43-64.		1
401	ARHGAP21 is a RhoGAP for RhoA and RhoC with a role in proliferation and migration of prostate adenocarcinoma cells. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 365-374.	1.8	50
402	Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer. Expert Opinion on Investigational Drugs, 2013, 22, 1385-1400.	1.9	12
403	Effectiveness of Bone Metastases Treatment by Sm-153 Oxabifore in Combination with Monoclonal Antibody Denosumab (Xgeva): First Experience. World Journal of Nuclear Medicine, 2013, 12, 19.	0.3	7
404	Cerebral Activation during Von Frey Filament Stimulation in Subjects with Endothelin-1-Induced Mechanical Hyperalgesia: A Functional MRI Study. BioMed Research International, 2013, 2013, 1-11.	0.9	2

#	Article	IF	Citations
405	Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases. Prostate, 2013, 73, 932-940.	1.2	53
406	A New Murine Model of Osteoblastic/Osteolytic Lesions from Human Androgen-Resistant Prostate Cancer. PLoS ONE, 2013, 8, e75092.	1.1	26
407	Endothelin-1 Promotes Survival and Chemoresistance in Chronic Lymphocytic Leukemia B Cells through ETA Receptor. PLoS ONE, 2014, 9, e98818.	1.1	33
408	Evidence for the endothelin system as an emerging therapeutic target for the treatment of chronic pain. Journal of Pain Research, 2014, 7, 531.	0.8	52
409	The Host Microenvironment Influences Prostate Cancer Invasion, Systemic Spread, Bone Colonization, and Osteoblastic Metastasis. Frontiers in Oncology, 2014, 4, 364.	1.3	50
410	Big endothelin changes the cellular miRNA environment in TMOb osteoblasts and increases mineralization. Connective Tissue Research, 2014, 55, 113-116.	1.1	13
411	Painful Boney Metastases. American Journal of Therapeutics, 2014, 21, 106-130.	0.5	27
412	Endothelin-1 induces interleukin-18 expression in human osteoblasts. Archives of Oral Biology, 2014, 59, 289-296.	0.8	15
413	Signaling Between Tumor Cells and the Host Bone Marrow Microenvironment. Calcified Tissue International, 2014, 94, 125-139.	1.5	22
414	Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies. Clinical and Experimental Metastasis, 2014, 31, 269-283.	1.7	31
415	Targeting tumorâ€“stromal interactions in bone metastasis. , 2014, 141, 222-233.		115
416	Managing bone metastases and reducing skeletal related events in prostate cancer. Nature Reviews Clinical Oncology, 2014, 11, 335-345.	12.5	110
417	Management of Castration Resistant Prostate Cancer. Current Clinical Urology, 2014, , .	0.0	2
418	Endothelin-1/Endothelin A receptor-mediated biased signaling is a new player in modulating human ovarian cancer cell tumorigenesis. Cellular Signalling, 2014, 26, 2885-2895.	1.7	25
419	Cocultures of Mesenchymal Stem Cells and Endothelial Cells As Organotypic Models of Prostate Cancer Metastasis. Molecular Pharmaceutics, 2014, 11, 2126-2133.	2.3	15
420	Serum big endothelin-1 as a clinical marker for cardiopulmonary and neoplastic diseases in dogs. Life Sciences, 2014, 118, 329-332.	2.0	12
421	The Association of Endothelinâ€1 Signaling with Bone Alkaline Phosphatase Expression and Protumorigenic Activities in Canine Osteosarcoma. Journal of Veterinary Internal Medicine, 2015, 29, 1584-1594.	0.6	5
422	Estrogen and estrogen receptor alpha promotes malignancy and osteoblastic tumorigenesis in prostate cancer. Oncotarget, 2015, 6, 44388-44402.	0.8	48

#	Article	IF	Citations
423	Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer. Yonsei Medical Journal, 2015, 56, 1206.	0.9	28
424	Expression and Functional Role of Orphan Receptor GPR158 in Prostate Cancer Growth and Progression. PLoS ONE, 2015, 10, e0117758.	1.1	34
425	Targeting Bone Metabolism in Patients with Advanced Prostate Cancer: Current Options and Controversies. International Journal of Endocrinology, 2015, 2015, 1-9.	0.6	28
426	The Molecule Mechanisms of Bone Metastasis in Breast Cancer. Journal of Orthopedic Oncology, 2015, 01, .	0.1	0
427	Stellate Cells and Portal Hypertension. , 2015, , 125-144.		2
428	Cancer-targeted therapies and radiopharmaceuticals. BoneKEy Reports, 2015, 4, 707.	2.7	2
429	Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800). Clinical Genitourinary Cancer, 2015, 13, 531-539.e1.	0.9	9
430	Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome. Clinical Cancer Research, 2015, 21, 3619-3630.	3.2	115
431	Big endothelin-1 as a tumour marker for canine haemangiosarcoma. Veterinary Journal, 2015, 204, 269-274.	0.6	12
432	Osteoblastic and Osteoclastic Metastases in a Single Vertebra-A Rare Presentation. Journal of Clinical and Diagnostic Research JCDR, 2015, 9, OD07-8.	0.8	0
433	Expression of endothelin-1 and endothelin-1 receptor A in canine mammary tumours. Research in Veterinary Science, 2015, 100, 182-188.	0.9	4
434	The emerging role of endothelin-1 in the pathogenesis of subchondral bone disturbance and osteoarthritis. Osteoarthritis and Cartilage, 2015, 23, 516-524.	0.6	37
435	Cytokines and bone cancers. , 2015, , 103-110.		0
436	Systemic treatment of bone metastases in castration-resistant prostate cancer (CRPC): pre-clinical to clinical point of view. , 2015, , 637-646.		1
437	Endothelial Dysfunction in Advanced Liver Disease. American Journal of the Medical Sciences, 2015, 349, 6-16.	0.4	17
438	The genetic basis of intradural spinal tumors and its impact on clinical treatment. Neurosurgical Focus, 2015, 39, E3.	1.0	43
439	Tumorâ€“bone interactions: there is no place like bone. , 2015, , 13-28.		0
440	Bone metastases in prostate cancer: pathophysiology, clinical complications, actual treatment, and future directions. , 2015, , 657-663.		1

#	Article	IF	Citations
441	Involvement of Ion Channels in Endothelin-1-induced Signalling in Human Prostate Cancer Cells. Journal of Cell Signaling, 2016, 01, .	0.3	6
442	Targeting the Bone Microenvironment in Metastatic Castration-Resistant Prostate Cancer. Current Drug Targets, 2016, 17, 276-289.	1.0	6
443	Short Anabolic Peptides for Bone Growth. Medicinal Research Reviews, 2016, 36, 579-640.	5.0	14
444	Endothelin-1 induces oncostatin M expression in osteoarthritis osteoblasts by trans-activating the oncostatin M gene promoter via Ets-1. Molecular Medicine Reports, 2016, 13, 3559-3566.	1.1	4
445	Galectin-3 in bone tumor microenvironment: a beacon for individual skeletal metastasis management. Cancer and Metastasis Reviews, 2016, 35, 333-346.	2.7	23
448	Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. Cancer Treatment Reviews, 2016, 44, 61-73.	3.4	56
449	Therapeutic potential of endothelin inhibitors in canine hemangiosarcoma. Life Sciences, 2016, 159, 55-60.	2.0	1
450	Hypercalcaemia and hypocalcaemia: finding the balance. Supportive Care in Cancer, 2017, 25, 1639-1649.	1.0	24
451	Molecular Involvement of the Bone Marrow Microenvironment in Bone Metastasis. , 2017, , 263-276.		1
452	Alkaline Phosphatase-Instructed Self-Assembly of Gadolinium Nanofibers for Enhanced T₂-Weighted Magnetic Resonance Imaging of Tumor. Analytical Chemistry, 2017, 89, 6922-6925.	3.2	66
453	The Bony Side of Endothelial Cells in Prostate Cancer. Developmental Cell, 2017, 41, 451-452.	3.1	3
454	Endothelin Signaling in Bone. Endocrinology and Metabolism Clinics of North America, 2017, 46, 51-62.	1.2	8
455	Targeting endothelin-1 receptor/Î²-arrestin1 network for the treatment of ovarian cancer. Expert Opinion on Therapeutic Targets, 2017, 21, 925-932.	1.5	9
456	Signaling of endothelin involves bone and soft tissue remodeling by modulating wound healing and tumor progression. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology, 2017, 29, 85-99.	0.2	1
458	Molecular Regulation of Bone Metastasis Pathogenesis. Cellular Physiology and Biochemistry, 2018, 46, 1423-1438.	1.1	52
459	Drug repurposing in kidney disease. Kidney International, 2018, 94, 40-48.	2.6	41
460	Osteoblast-secreted WISP-1 promotes adherence of prostate cancer cells to bone via the VCAM-1/integrin Î±4Î²1 system. Cancer Letters, 2018, 426, 47-56.	3.2	51
461	RANKL/RANK/OPG cytokine receptor system: mRNA expression pattern in BPH, primary and metastatic prostate cancer disease. World Journal of Urology, 2018, 36, 187-192.	1.2	15

#	Article	IF	Citations
462	The Biology of Bone Metastasis. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a031252.	2.9	123
463	DKK1 and Kremen Expression Predicts the Osteoblastic Response to Bone Metastasis. Translational Oncology, 2018, 11, 873-882.	1.7	22
464	Endothelin-1 traps as a potential therapeutic tool: from diabetes to beyond?. Drug Discovery Today, 2019, 24, 1937-1942.	3.2	10
465	Bone Target Therapy in Urologic Malignancies. , 2019, , 77-93.		0
466	Castration Determines the Efficacy of ETAR Blockade in a Mouse Model of Prostate Cancer Bone Metastasis. Endocrinology, 2019, 160, 1786-1796.	1.4	5
467	Decitabine attenuates nociceptive behavior in a murine model of bone cancer pain. Pain, 2019, 160, 619-631.	2.0	11
468	Diffuse osteosclerosis as a presentation of recurrent breast cancer: role of endothelin 1. Osteoporosis International, 2019, 30, 1699-1703.	1.3	1
469	Zoledronic acid for the treatment of prostate cancer. Expert Opinion on Pharmacotherapy, 2019, 20, 657-666.	0.9	23
470	Metastatic bone disease: Pathogenesis and therapeutic options. Journal of Bone Oncology, 2019, 15, 100205.	1.0	153
471	Clinicopathological Significance of the ET Axis in Human Oral Squamous Cell Carcinoma. Pathology and Oncology Research, 2019, 25, 1083-1089.	0.9	2
472	Multiple bone metastases: what the palliative care specialist should know about the potential, limitations and practical aspects of radiation therapy. Annals of Palliative Medicine, 2020, 9, 1307-1313.	0.5	1
473	Bone Tropism in Cancer Metastases. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a036848.	2.9	8
474	Ambrisentan, an endothelin receptor type A-selective antagonist, inhibits cancer cell migration, invasion, and metastasis. Scientific Reports, 2020, 10, 15931.	1.6	11
475	Bone metastases. Nature Reviews Disease Primers, 2020, 6, 83.	18.1	246
476	Breast Cancer and Microcalcifications: An Osteoimmunological Disorder?. International Journal of Molecular Sciences, 2020, 21, 8613.	1.8	13
477	Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. Journal of the National Cancer Institute, 2020, 112, 562-573.	3.0	45
478	Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy. Journal of Clinical Medicine, 2020, 9, 824.	1.0	64
479	Differences in Endothelin B Receptor Isoforms Expression and Function in Breast Cancer Cells. Journal of Cancer, 2020, 11, 2688-2701.	1.2	5

#	Article	IF	Citations
480	A case of ROS1-rearranged lung adenocarcinoma with osteoblastic bone metastasis. Respiratory Medicine Case Reports, 2020, 30, 101124.	0.2	1
481	Endothelin-1 enhances acid-sensing ion channel currents in rat primary sensory neurons. Acta Pharmacologica Sinica, 2020, 41, 1049-1057.	2.8	5
482	Recent advances in bone-targeted therapy. , 2020, 207, 107473.		38
483	Endothelins. , 2021, , 1-10.		0
484	Exploiting bone niches: progression of disseminated tumor cells to metastasis. Journal of Clinical Investigation, 2021, 131, .	3.9	17
485	Treatment and trials in non-metastatic castration-resistant prostate cancer. Nature Reviews Urology, 2021, 18, 433-442.	1.9	32
486	Endothelin-1 axes in the framework of predictive, preventive and personalised (3P) medicine. EPMA Journal, 2021, 12, 265-305.	3.3	46
487	Mechanisms of bone metastasis. Cancer, 1997, 80, 1546-1556.	2.0	362
488	Therapieoptionen des hormonrefraktÃren Prostatakarzinoms. , 2005, , 95-105.		1
489	The Search for Genes Which Influence Prostate Cancer Metastasis: A Moving Target?. Cancer Metastasis - Biology and Treatment, 2008, , 21-61.	0.1	2
490	Pathophysiology of Bone Metastases. Cancer Metastasis - Biology and Treatment, 2009, , 31-50.	0.1	3
491	Clinical Aspects of Bone Metastases in Prostate Cancer. Cancer Treatment and Research, 2004, 118, 23-46.	0.2	18
492	Endothelins in Bone Cancer Metastases. Cancer Treatment and Research, 2004, 118, 197-212.	0.2	50
493	Androgen Receptor in Prostate Cancer Progression. , 2008, , 129-146.		1
494	The Bone Microenvironment in Prostate Cancer Metastasis. Advances in Experimental Medicine and Biology, 2019, 1210, 171-184.	0.8	15
495	The Role of Bone Microenvironment, Vitamin D and Calcium. Recent Results in Cancer Research, 2012, 192, 33-64.	1.8	12
496	The Roles of Endothelins in Proliferation, Apoptosis, and Angiogenesis. Handbook of Experimental Pharmacology, 2001, , 299-322.	0.9	4
497	Cancer pain: causes, consequences and therapeutic opportunities. , 2006, , 1087-1097.		5

#	Article	IF	Citations
498	Metastatic Spine Tumors. , 2005, , 1025-1061.		2
499	Bone Metastases. , 2008, , 845-871.		2
500	Local Factors in Skeletal Malignancy. , 2002, , 1093-1104.		2
501	Molecular Mechanism of Prostate Cancer Invasion and Metastasis. , 2003, , 11-27.		2
502	Bone Metastases. , 2014, , 739-763.e3.		3
503	Prostate expression of endothelins and their receptors in rat growth. Reproduction, Fertility and Development, 2008, 20, 750.	0.1	1
504	The Effect of Oxygen and Carbon Dioxide on Tumor Cell Endothelin-1 Production. Journal of Cardiovascular Pharmacology, 1998, 31, S537-S540.	0.8	4
505	Plasma Endothelin Concentrations in Hypertension. Journal of Cardiovascular Pharmacology, 2000, 35, S25-S31.	0.8	26
506	EXPRESSION OF ENDOTHELIN RECEPTOR A ASSOCIATED WITH PROSTATE CANCER PROGRESSION. Journal of Urology, 2001, , 1033-1036.	0.2	2
507	Androgen receptorâ€“negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. Journal of Clinical Investigation, 2008, 118, 2697-710.	3.9	153
508	Overexpression of Endothelin 1 Triggers Hepatocarcinogenesis in Zebrafish and Promotes Cell Proliferation and Migration through the AKT Pathway. PLoS ONE, 2014, 9, e85318.	1.1	64
509	The activation of OR51E1 causes growth suppression of human prostate cancer cells. Oncotarget, 2016, 7, 48231-48249.	0.8	53
510	Oxidative Stress Induced Mitochondrial DNA Deletion as a Hallmark forthe Drug Development in the Context of the Cerebrovascular Diseases. Recent Patents on Cardiovascular Drug Discovery, 2011, 6, 222-241.	1.5	50
511	Mitochondrion-Specific Antioxidants as Drug Treatments for Alzheimer Disease. CNS and Neurological Disorders - Drug Targets, 2011, 10, 149-162.	0.8	54
512	Advances in the therapy of cancer pain: from novel experimental models to evidence-based treatments. Signa Vitae, 2007, 2, 23.	0.8	6
513	Optimal bone health management strategies in patients with prostate cancer. Indian Journal of Urology, 2013, 29, 89.	0.2	6
514	Prostate cancer progression and surrounding microenvironment. International Journal of Biological Markers, 2006, 21, 88-95.	0.7	14
515	Bone Health in Cancer Patients. UNIPA Springer Series, 2021, , 365-380.	0.1	0

#	Article	IF	Citations
516	Evolving cancerâ€“niche interactions and therapeutic targets during bone metastasis. Nature Reviews Cancer, 2022, 22, 85-101.	12.8	47
517	Endothelin Ligands and their Experimental Effects Within the Human Circulation. Handbook of Experimental Pharmacology, 2001, , 503-520.	0.9	0
518	Cell Signaling by Endothelin Peptides. Handbook of Experimental Pharmacology, 2001, , 115-140.	0.9	3
519	Molekulare Grundlagen des Prostatakarzinoms. , 2002, , 329-361.		0
521	Opportunities for Targeted Molecular Therapy for Prostate Cancer. , 2004, , 631-652.		0
522	Prostate Cancer: Models for Developing Novel Therapeutic Approaches. Cancer Metastasis - Biology and Treatment, 2004, , 163-186.	0.1	0
523	Bone-Targeted Therapy for Prostate Cancer. , 2004, , 589-606.		1
524	The Effects of Selective Cyclooxygenase-2 Inhibitor and Prostaglandin E₂Receptor Agonists on the Endothelin Axis of Prostate Cancer Cells. Korean Journal of Urology, 2006, 47, 195.	0.2	0
525	Pain Due to Bone Metastases: New Research Issues and Their Clinical Implications. , 2006, , 75-84.		0
526	The Endothelin Pathway and its Modulation in Prostate Cancer. Translational Medicine Series, 2006, , 59-74.	0.0	0
527	Dolor oncolÃ³gico. , 2007, , 1115-1125.		0
529	Kinins and Endothelin. , 2008, , 385-411.		1
530	Skeletal Complications: Bone Metabolism and Novel Targeted Agents. Translational Medicine Series, 2008, , 1-24.	0.0	0
532	Pathophysiology of Prostate Cancer Bone Metastasis. , 2010, , 245-254.		0
533	Endothelin Receptors as Therapeutic Targets in Castration-Resistant Prostate Cancer. , 2010, , 277-286.		0
534	Bone Metastases of Prostatic Cancer. , 2010, , 449-456.		0
535	Cell Biology of Prostate Cancer and Molecular Targets. , 2010, , 1-24.		0
536	Challenges for the Development of New Agents in Prostate Cancer. , 2010, , 389-397.		0

#	Article	IF	Citations
537	Malignant Pleural Effusion and Osteoblastic Metastases as the Initial Manifestation of Occult Gastric Cancer :. Kitakanto Medical Journal, 2011, 61, 515-518.	0.0	0
538	Anti-angiogenic therapy for prostate cancer: rationale and ongoing trials. Clinical Investigation, 2011, 1, 1651-1661.	0.0	0
539	The Interplay between the Androgen Receptor, Soluble Factors and Tumour Microenvironment. Journal of Steroids & Hormonal Science, 2012, s2, .	0.1	1
540	Role of Connective Tissue Growth Factor (CTGF/CCN2) in Oral Squamous Cell Carcinoma-Induced Bone Destruction. , 0, , .		0
541	Chemotherapy and Novel Systemic Approaches in the Treatment of Metastatic Castration Resistant Prostate Cancer. , 2013, , 901-923.		0
542	Bone-Targeted Therapy: Rationale and Current Status. Current Clinical Urology, 2014, , 139-153.	0.0	0
543	Prostatakarzinom. , 2014, , 513-676.		0
544	Interaktion von Tumorzellen und Knochen bei osteolytischen/osteosklerotischen Metastasen, Circulus vitiosus der Knochenmetastasierung. , 2014, , 13-21.		0
545	Endothelin Signaling to the Nucleus: Regulation of Gene Expression and Phenotype. , 1998, , 163-176.		0
547	Bone Target Therapy in Urologic Malignancies. , 2017, , 1-16.		0
548	Endothelin-1 expression in prostate needle biopsy specimens correlated with aggressiveness of prostatic cancer. Iranian Journal of Pathology, 2017, 12, 171-176.	0.2	1
549	Metastatic Prostate Cancer. Molecular Pathology Library, 2018, , 279-295.	0.1	1
550	Skeletal Complications in Patients with CRPC. , 2018, , 327-338.		0
551	Role of Osteoblasts in Cancer-Induced Bone Disease. , 2020, , 201-218.		1
552	Bone as a New Milieu for Disseminated Tumor Cells: An Overview of Bone Metastasis. , 2020, , 78-95.		0
553	Influence of the Bone Microenvironment on Breast Cancer Metastasis to Bone. , 2005, , 149-164.		1
554	Discoveries and Frontiers in Prostate Cancer Translational Sciences. , 2006, , 743-751.		0
556	Intercellular Targets of Prostate Cancer. , 2007, , 475-486.		0

#	Article	IF	Citations
557	New Perspectives on Chemotherapy in Prostate Cancer. , 2008, , 401-425.		0
558	Epigenetic Gene Silencing in Prostate Cancer. , 2008, , 17-52.		0
561	Prostatakarzinom. , 2014, , 513-676.		0
562	Endothelin-a receptor antagonists and advanced prostate cancer. Reviews in Urology, 2004, 6, 47-8.	0.9	4
563	The future in advanced prostate cancer: take your partners or is the last dance for me?. Reviews in Urology, 2004, 6 Suppl 10, S29-44.	0.9	1
564	Angiogenesis in cancer: the role of endothelin-1. Annals of the Royal College of Surgeons of England, 1999, 81, 306-10.	0.3	26
565	Bisphosphonate therapy for women with breast cancer and at high risk for osteoporosis. Journal of the National Medical Association, 2007, 99, 35-45.	0.6	3
566	Endothelin-1 Expression in Prostate Needle Biopsy Specimens Correlated With Aggressiveness of Prostatic Cancer. Iranian Journal of Pathology, 2017, 12, 171-176.	0.2	1
567	Prostate cancer metastasis and soy isoflavones: a dogfight over a bone. EXCLI Journal, 2019, 18, 106-126.	0.5	4
568	Endothelins. , 2021, , 606-615.		0
569	A Tailored Approach for Appendicular Impending and Pathologic Fractures in Solid Cancer Metastases. Cancers, 2022, 14, 893.	1.7	2
570	Antinociceptive effect of garlic, garlic preparations and derivative compounds. European Journal of Pain, 2022, 26, 947-964.	1.4	6
571	Bone metastases in non-small cell lung cancer: a narrative review. Journal of Thoracic Disease, 2022, 14, 1696-1712.	0.6	11
572	Tumor Innervation: History, Methodologies, and Significance. Cancers, 2022, 14, 1979.	1.7	8
573	Mechanisms of disease-related pain in cancer: insights from the study of bone tumors. , 0, , 32-40.		0
574	Novel Molecular and Genetic Prognostic Biomarkers in Prostate Cancer. , 2005, , 377-391.		0
575	Hormone-Refractory Prostate Cancer. , 2008, , 1417-1417.		0
576	Endothelin-1-mediated miR-let-7g-5p triggers interlukin-6 and TNF-Î± to cause myopathy and chronic adipose inflammation in elderly patients with diabetes mellitus. Aging, 2022, 14, 3633-3651.	1.4	7

#	Article	IF	Citations
577	Bone Metastases: From Mechanisms to Treatment. Seminars in Oncology Nursing, 2022, , 151277.	0.7	5
578	Investigating the specificity of endothelin-traps as a potential therapeutic tool for endothelin-1 related disorders. World Journal of Diabetes, 2022, 13, 434-441.	1.3	1
579	The 100 most cited papers on bone metastasis: A bibliometric analysis. Journal of Bone Oncology, 2022, 35, 100443.	1.0	3
580	Antagonizing exosomal miR-18a-5p derived from prostate cancer cells ameliorates metastasis-induced osteoblastic lesions by targeting Hist1h2bc and activating Wnt/Î²-catenin pathway. Genes and Diseases, 2022, , .	1.5	2
582	Bone Metastases: Systemic Regulation and Impact on Host. , 2022, , 41-49.		0
583	Loss of inhibition over master pathways of bone mass regulation results in osteosclerotic bone metastases in prostate cancer. Swiss Medical Weekly, 0, , .	0.8	2
585	PECAM1 plays a role in the pathogenesis and treatment of bone metastases. Frontiers in Genetics, 0, 14, .	1.1	0
590	Basic Insights into Tumor Microenvironment in Prostate Cancer. , 2024, , 43-71.		0